Breaking News Instant updates and real-time market news.

MYOV

Myovant Sciences

$11.61 /

+0.07 (+0.61%)

07:32
04/22/20
04/22
07:32
04/22/20
07:32

Myovant Sciences says co-primary endpoints met in Phase 3 SPIRIT 2 study

Myovant Sciences announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix combination therapy in women with pain associated with endometriosis, met its co-primary efficacy endpoints and six key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated including minimal bone mineral density loss over 24 weeks. Myovant also announced that, in a separate clinical study, relugolix combination therapy achieved 100% ovulation inhibition in 67 healthy women with no women ovulating during the 84-day treatment period, as evaluated by the Hoogland-Skouby assessment scale. Furthermore, 100% of women resumed ovulation or menses upon discontinuation of treatment with an average time to ovulation of 23.5 days. In the co-primary endpoint analysis of SPIRIT 2, 75.2% of women receiving once-daily relugolix combination therapy achieved a clinically-meaningful reduction in dysmenorrhea versus 30.4% of women in the placebo group. For non-menstrual pelvic pain, relugolix combination therapy achieved a clinically-meaningful reduction in 66.0% of women versus 42.6% women in the placebo group. On average, women receiving relugolix combination therapy had a 75.1% reduction on the 11-point Numerical Rating Scale for dysmenorrhea from 7.2 to 1.7. Six key secondary endpoints measured at Week 24 and compared to placebo achieved statistical significance, including changes in mean dysmenorrhea and overall pelvic pain, impact of pain on daily activities as measured by the Endometriosis Health Profile-30 pain domain, a greater proportion of women not using opioids, changes in non-menstrual pelvic pain, and dyspareunia. Relugolix combination therapy was generally well-tolerated with minimal bone mineral density loss over 24 weeks. The overall incidence of adverse events in the relugolix combination and placebo groups was similar. In the relugolix combination therapy group, 5.3% of women discontinued treatment early due to adverse events versus 3.9% in the placebo group. The most frequently reported adverse events, reported in at least 10% of women in the relugolix combination group, were headache, nasopharyngitis, and hot flashes. There were three pregnancies in the relugolix combination group and five in the placebo group.

MYOV Myovant Sciences
$11.61 /

+0.07 (+0.61%)

02/03/20 Citi
Myovant Sciences resumed with a Neutral from Buy at Citi
11/19/19 Goldman Sachs
Myovant Sciences price target raised to $20 from $18 at Goldman Sachs
11/19/19 JMP Securities
JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data
08/28/19
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Earnings
Marvell sees Q1 adjusted EPS 23c-31c, consensus 27c » 16:06
03/03/21
03/03
16:06
03/03/21
16:06
MRVL

Marvell

$45.70 /

-2.1 (-4.39%)

Sees Q1 revenue $800M +/-…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$45.70 /

-2.1 (-4.39%)

MRVL Marvell
$45.70 /

-2.1 (-4.39%)

03/02/21 Susquehanna
Marvell results expected to be a modest beat, says Susquehanna
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
01/26/21 Barclays
Marvell price target raised to $60 from $50 at Barclays
MRVL Marvell
$45.70 /

-2.1 (-4.39%)

MRVL Marvell
$45.70 /

-2.1 (-4.39%)

MRVL Marvell
$45.70 /

-2.1 (-4.39%)

MRVL Marvell
$45.70 /

-2.1 (-4.39%)

Hot Stocks
Provention Bio's teplizumab shows efficacy in delaying type 1 diabetes » 16:06
03/03/21
03/03
16:06
03/03/21
16:06
PRVB

Provention Bio

$11.72 /

-0.59 (-4.79%)

Provention Bio announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PRVB Provention Bio
$11.72 /

-0.59 (-4.79%)

PRVB Provention Bio
$11.72 /

-0.59 (-4.79%)

02/25/21 Chardan
Provention Bio price target lowered to $35 from $40 at Chardan
02/22/21 H.C. Wainwright
Provention Bio price target raised to $34 from $26 at H.C. Wainwright
01/04/21 Chardan
Provention Bio price target raised to $40 from $35 at Chardan
11/02/20 Chardan
Provention Bio remains top pick for 2020 at Chardan
PRVB Provention Bio
$11.72 /

-0.59 (-4.79%)

  • 14
    Jan
  • 18
    Jun
PRVB Provention Bio
$11.72 /

-0.59 (-4.79%)

Earnings
Splunk sees Q1 revenue $480M-$500M, consensus $507.29M » 16:06
03/03/21
03/03
16:06
03/03/21
16:06
SPLK

Splunk

$143.58 /

-5.42 (-3.64%)

Sees Q1 ARR…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

06:33 Today Citi
Splunk assumed with a Neutral at Citi
03/02/21 RBC Capital
Splunk may see 'slight upside' in Q4 results, says RBC Capital
02/24/21 Jefferies
Jefferies remains a buyer of Splunk, sees 'favorable set-up' into earnings
02/17/21 Mizuho
Splunk price target raised to $190 from $180 at Mizuho
SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

Earnings
Splunk reports Q4 EPS (86c) vs (15c) last year » 16:05
03/03/21
03/03
16:05
03/03/21
16:05
SPLK

Splunk

$143.58 /

-5.42 (-3.64%)

Reports Q4 revenue $745M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

06:33 Today Citi
Splunk assumed with a Neutral at Citi
03/02/21 RBC Capital
Splunk may see 'slight upside' in Q4 results, says RBC Capital
02/24/21 Jefferies
Jefferies remains a buyer of Splunk, sees 'favorable set-up' into earnings
02/17/21 Mizuho
Splunk price target raised to $190 from $180 at Mizuho
SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

SPLK Splunk
$143.58 /

-5.42 (-3.64%)

Earnings
Marvell reports Q4 adjusted EPS 29c, consensus 29c » 16:05
03/03/21
03/03
16:05
03/03/21
16:05
MRVL

Marvell

$45.73 /

-2.07 (-4.33%)

Reports Q4 revenue $798M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$45.73 /

-2.07 (-4.33%)

MRVL Marvell
$45.73 /

-2.07 (-4.33%)

03/02/21 Susquehanna
Marvell results expected to be a modest beat, says Susquehanna
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
01/26/21 Barclays
Marvell price target raised to $60 from $50 at Barclays
MRVL Marvell
$45.73 /

-2.07 (-4.33%)

MRVL Marvell
$45.73 /

-2.07 (-4.33%)

MRVL Marvell
$45.73 /

-2.07 (-4.33%)

MRVL Marvell
$45.73 /

-2.07 (-4.33%)

Earnings
Snowflake sees FY22 product revenue $1.00B-$1.02B, consensus $1.10B  16:04
03/03/21
03/03
16:04
03/03/21
16:04
SNOW

Snowflake

$249.40 /

-21.19 (-7.83%)

 
ShowHide Related Items >><<
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

01/21/21 Goldman Sachs
Snowflake initiated with a Neutral at Goldman Sachs
01/19/21 Rosenblatt
Snowflake initiated with a Neutral at Rosenblatt
01/15/21 Credit Suisse
Snowflake price target raised to $310 from $265 at Credit Suisse
01/13/21 Citi
Snowflake price target raised to $325 from $300 at Citi
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

  • 16
    Sep
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

Earnings
Snowflake sees Q1 product revenue revenue $195M-$200M, consensus $213.06M.  16:04
03/03/21
03/03
16:04
03/03/21
16:04
SNOW

Snowflake

$249.40 /

-21.19 (-7.83%)

 
ShowHide Related Items >><<
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

01/21/21 Goldman Sachs
Snowflake initiated with a Neutral at Goldman Sachs
01/19/21 Rosenblatt
Snowflake initiated with a Neutral at Rosenblatt
01/15/21 Credit Suisse
Snowflake price target raised to $310 from $265 at Credit Suisse
01/13/21 Citi
Snowflake price target raised to $325 from $300 at Citi
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

  • 16
    Sep
SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

SNOW Snowflake
$249.40 /

-21.19 (-7.83%)

Hot Stocks
Okta to acquire Auth0 in deal valued at roughly $6.5B » 16:04
03/03/21
03/03
16:04
03/03/21
16:04
OKTA

Okta

$242.57 /

-16.445 (-6.35%)

Okta announced it has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$242.57 /

-16.445 (-6.35%)

OKTA Okta
$242.57 /

-16.445 (-6.35%)

03/02/21 RBC Capital
Okta price target raised to $300 from $264 at RBC Capital
02/23/21 Deutsche Bank
Okta initiated with a Buy at Deutsche Bank
02/17/21 Mizuho
Okta price target raised to $305 from $270 at Mizuho
02/16/21 Canaccord
Okta price target raised to $300 from $250 at Canaccord
OKTA Okta
$242.57 /

-16.445 (-6.35%)

OKTA Okta
$242.57 /

-16.445 (-6.35%)

OKTA Okta
$242.57 /

-16.445 (-6.35%)

Earnings
Descartes Systems reports Q4 EPS 20c, consensus 16c » 16:04
03/03/21
03/03
16:04
03/03/21
16:04
DSGX

Descartes Systems

$58.19 /

-1.68 (-2.81%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DSGX Descartes Systems
$58.19 /

-1.68 (-2.81%)

DSGX Descartes Systems
$58.19 /

-1.68 (-2.81%)

01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
11/13/20 Stephens
Descartes Systems upgraded to Overweight from Equal Weight at Stephens
09/11/20 Stifel
Descartes Systems price target raised to C$78 from C$63 at Stifel
09/11/20 Canaccord
Descartes Systems price target raised to C$65 from C$50 at Canaccord
DSGX Descartes Systems
$58.19 /

-1.68 (-2.81%)

DSGX Descartes Systems
$58.19 /

-1.68 (-2.81%)

Syndicate
Tyler Technologies announces offering of convertible senior notes » 16:04
03/03/21
03/03
16:04
03/03/21
16:04
TYL

Tyler Technologies

$441.67 /

-27.1 (-5.78%)

Tyler Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TYL Tyler Technologies
$441.67 /

-27.1 (-5.78%)

TYL Tyler Technologies
$441.67 /

-27.1 (-5.78%)

02/12/21 DA Davidson
Tyler Technologies price target raised to $395 from $370 at DA Davidson
02/11/21 Northcoast
NIC Inc. downgraded to Neutral from Buy at Northcoast
02/11/21 Barrington
NIC Inc. downgraded to Underperform from Outperform at Barrington
02/11/21 JMP Securities
Tyler Technologies price target raised to $480 from $435 at JMP Securities
TYL Tyler Technologies
$441.67 /

-27.1 (-5.78%)

TYL Tyler Technologies
$441.67 /

-27.1 (-5.78%)

TYL Tyler Technologies
$441.67 /

-27.1 (-5.78%)

Earnings
Soleno Therapeutics reports Q4 EPS (4c), consensus (7c) » 16:03
03/03/21
03/03
16:03
03/03/21
16:03
SLNO

Soleno Therapeutics

$2.64 /

+ (+0.00%)

The fair value of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLNO Soleno Therapeutics
$2.64 /

+ (+0.00%)

SLNO Soleno Therapeutics
$2.64 /

+ (+0.00%)

09/29/20 Guggenheim
Soleno Therapeutics initiated with a Buy at Guggenheim
04/07/20 Craig-Hallum
Millendo failure in PWS doesn't add risk to Soleno readout, says Craig-Hallum
SLNO Soleno Therapeutics
$2.64 /

+ (+0.00%)

  • 24
    Jun
Earnings
Snowflake reports Q4 EPS (70c), consensus (17c) » 16:03
03/03/21
03/03
16:03
03/03/21
16:03
SNOW

Snowflake

$250.42 /

-20.17 (-7.45%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

01/21/21 Goldman Sachs
Snowflake initiated with a Neutral at Goldman Sachs
01/19/21 Rosenblatt
Snowflake initiated with a Neutral at Rosenblatt
01/15/21 Credit Suisse
Snowflake price target raised to $310 from $265 at Credit Suisse
01/13/21 Citi
Snowflake price target raised to $325 from $300 at Citi
SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

  • 16
    Sep
SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

SNOW Snowflake
$250.42 /

-20.17 (-7.45%)

Earnings
Okta sees FY22 adjusted EPS (49c)-(44c), consensus 1c » 16:03
03/03/21
03/03
16:03
03/03/21
16:03
OKTA

Okta

$242.72 /

-16.295 (-6.29%)

Sees FY22 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$242.72 /

-16.295 (-6.29%)

OKTA Okta
$242.72 /

-16.295 (-6.29%)

03/02/21 RBC Capital
Okta price target raised to $300 from $264 at RBC Capital
02/23/21 Deutsche Bank
Okta initiated with a Buy at Deutsche Bank
02/17/21 Mizuho
Okta price target raised to $305 from $270 at Mizuho
02/16/21 Canaccord
Okta price target raised to $300 from $250 at Canaccord
OKTA Okta
$242.72 /

-16.295 (-6.29%)

OKTA Okta
$242.72 /

-16.295 (-6.29%)

OKTA Okta
$242.72 /

-16.295 (-6.29%)

Earnings
Okta sees Q1 adjusted EPS (21c)-(20c), consensus (7c) » 16:02
03/03/21
03/03
16:02
03/03/21
16:02
OKTA

Okta

$242.34 /

-16.675 (-6.44%)

Sees Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

03/02/21 RBC Capital
Okta price target raised to $300 from $264 at RBC Capital
02/23/21 Deutsche Bank
Okta initiated with a Buy at Deutsche Bank
02/17/21 Mizuho
Okta price target raised to $305 from $270 at Mizuho
02/16/21 Canaccord
Okta price target raised to $300 from $250 at Canaccord
OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

Earnings
Okta reports Q4 adjusted EPS 6c, consensus (1c) » 16:02
03/03/21
03/03
16:02
03/03/21
16:02
OKTA

Okta

$242.34 /

-16.675 (-6.44%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

03/02/21 RBC Capital
Okta price target raised to $300 from $264 at RBC Capital
02/23/21 Deutsche Bank
Okta initiated with a Buy at Deutsche Bank
02/17/21 Mizuho
Okta price target raised to $305 from $270 at Mizuho
02/16/21 Canaccord
Okta price target raised to $300 from $250 at Canaccord
OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

OKTA Okta
$242.34 /

-16.675 (-6.44%)

Hot Stocks
LivaNova up 3% after FT reports on Permira takeover bid  16:00
03/03/21
03/03
16:00
03/03/21
16:00
LIVN

LivaNova

$75.44 /

-0.775 (-1.02%)

 
ShowHide Related Items >><<
LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

09:53 Today
Fly Intel: Top five analyst downgrades
07:03 Today Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
05:24 Today Berenberg
LivaNova downgraded to Hold from Buy at Berenberg
02/24/21 Piper Sandler
LivaNova price target raised to $81 from $73 at Piper Sandler
LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

Periodicals
PE firm Permira has made bid to buy LivaNova, FT reports » 15:58
03/03/21
03/03
15:58
03/03/21
15:58
LIVN

LivaNova

$75.44 /

-0.775 (-1.02%)

Private equity group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

09:53 Today
Fly Intel: Top five analyst downgrades
07:03 Today Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
05:24 Today Berenberg
LivaNova downgraded to Hold from Buy at Berenberg
02/24/21 Piper Sandler
LivaNova price target raised to $81 from $73 at Piper Sandler
LIVN LivaNova
$75.44 /

-0.775 (-1.02%)

Conference/Events
The Washington Association of Money Managers holds a virtual event » 15:55
03/03/21
03/03
15:55
03/03/21
15:55
IVZ

Invesco

$23.89 /

-0.06 (-0.25%)

David Wertheim, Portfolio…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IVZ Invesco
$23.89 /

-0.06 (-0.25%)

IVZ Invesco
$23.89 /

-0.06 (-0.25%)

01/28/21
Fly Intel: Top five analyst upgrades
01/28/21
Invesco upgraded to Buy from Neutral at UBS
01/28/21 UBS
Invesco upgraded to Buy from Neutral at UBS
01/27/21 BMO Capital
Invesco price target raised to $22 from $19 at BMO Capital
IVZ Invesco
$23.89 /

-0.06 (-0.25%)

IVZ Invesco
$23.89 /

-0.06 (-0.25%)

IVZ Invesco
$23.89 /

-0.06 (-0.25%)

IVZ Invesco
$23.89 /

-0.06 (-0.25%)

Syndicate
Alignment Healthcare files for IPO, applies to list on Nasdaq with symbol 'ALHC' » 15:53
03/03/21
03/03
15:53
03/03/21
15:53
ALHC

Alignment Healthcare

$0.00 /

+ (+0.00%)

Alignment Healthcare has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
Vroom options imply 20.7% move in share price post-earnings » 15:34
03/03/21
03/03
15:34
03/03/21
15:34
VRM

Vroom

$44.74 /

-3.11 (-6.50%)

Pre-earnings options…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$44.74 /

-3.11 (-6.50%)

VRM Vroom
$44.74 /

-3.11 (-6.50%)

02/24/21 Jefferies
Carvana well positioned for 'beat/raise' earnings report, says Jefferies
02/16/21 Wells Fargo
Vroom price target raised to $60 from $55 at Wells Fargo
01/05/21 Stifel
Stifel adds Vroom to Select List, removes Buy-rated Peloton
12/17/20
Fly Intel: Top five analyst initiations
VRM Vroom
$44.74 /

-3.11 (-6.50%)

  • 07
    Dec
  • 11
    Sep
  • 09
    Jun
VRM Vroom
$44.74 /

-3.11 (-6.50%)

VRM Vroom
$44.74 /

-3.11 (-6.50%)

Recommendations
National Vision price target raised to $55 at Wells Fargo after Q4 results » 15:32
03/03/21
03/03
15:32
03/03/21
15:32
EYE

National Vision

$48.43 /

+0.67 (+1.40%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EYE National Vision
$48.43 /

+0.67 (+1.40%)

01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital on valuation
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
11/18/20 Berenberg
National Vision downgraded to Hold from Buy at Berenberg
EYE National Vision
$48.43 /

+0.67 (+1.40%)

EYE National Vision
$48.43 /

+0.67 (+1.40%)

Recommendations
Wells Fargo lowers Wendy's target to $22 as current performance misses mark » 15:29
03/03/21
03/03
15:29
03/03/21
15:29
WEN

Wendy's

$20.48 /

-0.82 (-3.85%)

Wells Fargo analyst Jon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WEN Wendy's
$20.48 /

-0.82 (-3.85%)

WEN Wendy's
$20.48 /

-0.82 (-3.85%)

02/26/21 Stephens
Wendy's named Best Idea at Stephens
01/27/21
Fly Intel: Top five analyst upgrades
01/27/21 Deutsche Bank
Wendy's upgraded to Buy with $25 target at Deutsche Bank
01/27/21 Deutsche Bank
Wendy's upgraded to Buy from Hold at Deutsche Bank
WEN Wendy's
$20.48 /

-0.82 (-3.85%)

WEN Wendy's
$20.48 /

-0.82 (-3.85%)

Recommendations
Michaels deal with Apollo Global 'a win for shareholders,' says Wells Fargo » 15:28
03/03/21
03/03
15:28
03/03/21
15:28
MIK

Michaels

$22.07 /

+4.04 (+22.41%)

, APO

Apollo Global

$50.76 /

+0.87 (+1.74%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MIK Michaels
$22.07 /

+4.04 (+22.41%)

APO Apollo Global
$50.76 /

+0.87 (+1.74%)

MIK Michaels
$22.07 /

+4.04 (+22.41%)

01/20/21 Morgan Stanley
Morgan Stanley downgrades Michaels to Underweight, sees 'too much optimism'
01/20/21 Morgan Stanley
Michaels downgraded to Underweight from Equal Weight at Morgan Stanley
12/14/20 JPMorgan
Michaels downgraded to Neutral after recent rally at JPMorgan
12/14/20 JPMorgan
Michaels downgraded to Neutral from Overweight at JPMorgan
APO Apollo Global
$50.76 /

+0.87 (+1.74%)

10:02 Today Stifel
Las Vegas Sands casino sale news 'clearly a positive,' says Stifel
01/20/21 Truist
Athene Holding price target raised to $55 from $48 at Truist
01/11/21 Wells Fargo
Apollo Global price target raised to $55 from $50 at Wells Fargo
12/18/20 Deutsche Bank
Apollo Global price target raised to $51 from $49 at Deutsche Bank
MIK Michaels
$22.07 /

+4.04 (+22.41%)

APO Apollo Global
$50.76 /

+0.87 (+1.74%)

MIK Michaels
$22.07 /

+4.04 (+22.41%)

APO Apollo Global
$50.76 /

+0.87 (+1.74%)

MIK Michaels
$22.07 /

+4.04 (+22.41%)

APO Apollo Global
$50.76 /

+0.87 (+1.74%)

MIK Michaels
$22.07 /

+4.04 (+22.41%)

APO Apollo Global
$50.76 /

+0.87 (+1.74%)

Options
United Continental call volume above normal and directionally bullish » 15:25
03/03/21
03/03
15:25
03/03/21
15:25
UAL

United Airlines

$54.87 /

+1.66 (+3.12%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UAL United Airlines
$54.87 /

+1.66 (+3.12%)

UAL United Airlines
$54.87 /

+1.66 (+3.12%)

02/22/21
Fly Intel: Top five analyst upgrades
02/22/21 Deutsche Bank
Deutsche upgrades eight airlines with Covid trending in right direction
02/22/21 Deutsche Bank
United Airlines upgraded to Buy from Hold at Deutsche Bank
02/17/21 BofA
Mesa Air double-upgraded to Buy from Underperform at BofA
UAL United Airlines
$54.87 /

+1.66 (+3.12%)

  • 22
    Apr
UAL United Airlines
$54.87 /

+1.66 (+3.12%)

UAL United Airlines
$54.87 /

+1.66 (+3.12%)

UAL United Airlines
$54.87 /

+1.66 (+3.12%)

Periodicals
Luminex jumps 8% after Bloomberg says company exploring sale » 15:22
03/03/21
03/03
15:22
03/03/21
15:22
LMNX

Luminex

$32.16 /

+2.25 (+7.52%)

, DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Bloomberg, which…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LMNX Luminex
$32.16 /

+2.25 (+7.52%)

DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

LMNX Luminex
$32.16 /

+2.25 (+7.52%)

02/18/21 Piper Sandler
Luminex shares are undervalued, says Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
11/06/20 Piper Sandler
Luminex's new product launches can drive long-term growth, says Piper Sandler
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

12/10/20 Exane BNP Paribas
DiaSorin SpA price target raised to EUR 145 from EUR 135 at Exane BNP Paribas
12/10/20 Kepler Cheuvreux
DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
12/10/20 Kepler Cheuvreux
DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
12/09/20 Morgan Stanley
DiaSorin SpA initiated with an Equal Weight at Morgan Stanley
LMNX Luminex
$32.16 /

+2.25 (+7.52%)

LMNX Luminex
$32.16 /

+2.25 (+7.52%)

DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

LMNX Luminex
$32.16 /

+2.25 (+7.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.